Engineering exosite peptides for complete inhibition of factor VIIa using a protease switch with substrate phage.
Maun HR, Eigenbrot C, Lazarus RA.
Maun HR, et al. Among authors: eigenbrot c.
J Biol Chem. 2003 Jun 13;278(24):21823-30. doi: 10.1074/jbc.M300951200. Epub 2003 Mar 25.
J Biol Chem. 2003.
PMID: 12657647
Free article.
Limitations of current anticoagulant therapies have led us to develop two distinct classes of exosite peptide inhibitors for the initiator of the clotting process, the tissue factor-factor VIIa (TF.FVIIa) complex (Roberge, M., Santell, L., Dennis, M. S., Eigenbrot, C …
Limitations of current anticoagulant therapies have led us to develop two distinct classes of exosite peptide inhibitors for the initiator o …